Details for New Drug Application (NDA): 050322
✉ Email this page to a colleague
NDA 050322 describes NEODECADRON, which is a drug marketed by Merck and is included in two NDAs. Additional details are available on the NEODECADRON profile page.
The generic ingredient in NEODECADRON is dexamethasone sodium phosphate; neomycin sulfate. There are thirty-nine drug master file entries for this compound. Additional details are available on the dexamethasone sodium phosphate; neomycin sulfate profile page.
The generic ingredient in NEODECADRON is dexamethasone sodium phosphate; neomycin sulfate. There are thirty-nine drug master file entries for this compound. Additional details are available on the dexamethasone sodium phosphate; neomycin sulfate profile page.
Summary for 050322
| Tradename: | NEODECADRON |
| Applicant: | Merck |
| Ingredient: | dexamethasone sodium phosphate; neomycin sulfate |
| Patents: | 0 |
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | SOLUTION/DROPS;OPHTHALMIC | Strength | EQ 0.1% PHOSPHATE;EQ 3.5MG BASE/ML | ||||
| Approval Date: | Approved Prior to Jan 1, 1982 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
